{"id":14637,"date":"2025-07-16T14:48:43","date_gmt":"2025-07-16T14:48:43","guid":{"rendered":"https:\/\/www.rawoodfoundation.org\/?p=14637"},"modified":"2025-10-29T13:00:38","modified_gmt":"2025-10-29T13:00:38","slug":"nouvelles-frontieres-dans-la-recherche-sur-lobesite-hypothalamique","status":"publish","type":"post","link":"https:\/\/www.rawoodfoundation.org\/fr\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/","title":{"rendered":"Nouvelles fronti\u00e8res de la recherche sur l'ob\u00e9sit\u00e9 hypothalamique"},"content":{"rendered":"

Les essais cliniques en cours et les donn\u00e9es r\u00e9cemment publi\u00e9es offrent un espoir pour l'HO<\/h2>\n\n\n\n

Pour les survivants de tumeurs hypothalamo-hypophysaires, en particulier les craniopharyngiomes, l'ob\u00e9sit\u00e9 hypothalamique est l'un des effets \u00e0 long terme les plus difficiles et les plus perturbants. Elle n'est pas due \u00e0 des choix de mode de vie, mais \u00e0 des l\u00e9sions de la partie du cerveau responsable de la r\u00e9gulation de la faim, de l'\u00e9quilibre \u00e9nerg\u00e9tique et du m\u00e9tabolisme. Les strat\u00e9gies conventionnelles de r\u00e9gime et d'exercice physique sont souvent inefficaces, laissant les patients avec peu d'options et un sentiment de d\u00e9sespoir.<\/p>\n\n\n\n

Cela commence \u00e0 changer.<\/strong><\/p>\n\n\n\n

Les chercheurs et les d\u00e9veloppeurs de produits pharmaceutiques se concentrent d\u00e9sormais sur l'HO, en d\u00e9veloppant des m\u00e9dicaments cibl\u00e9s. Traitements hypothalamiques de l'ob\u00e9sit\u00e9<\/a> qui refl\u00e8tent la biologie unique et les d\u00e9fis de cette maladie. Vous trouverez ci-dessous un r\u00e9sum\u00e9 des essais cliniques qui recrutent actuellement des participants, ainsi que de ceux qui ont achev\u00e9 des phases cl\u00e9s et publi\u00e9 des donn\u00e9es. Ces \u00e9tudes fa\u00e7onnent l'avenir des soins pour l'HO et pourraient bient\u00f4t apporter des th\u00e9rapies indispensables aux patients et aux familles qui ont longtemps \u00e9t\u00e9 mal desservis.<\/p>\n\n\n\n

Recrutement actif d'essais<\/strong><\/h3>\n\n\n\n

Phentermine\/Topiramate pour l'ob\u00e9sit\u00e9 hypothalamique<\/strong>
Cette \u00e9tude de phase 2 examine l'utilisation d'une combinaison de m\u00e9dicaments - la pentermine, un coupe-faim, et le topiramate, qui a un impact sur les fringales et la consommation d'\u00e9nergie - d\u00e9j\u00e0 approuv\u00e9e par la FDA pour l'ob\u00e9sit\u00e9 g\u00e9n\u00e9rale. L'essai \u00e9value la s\u00e9curit\u00e9 et l'efficacit\u00e9 de ce m\u00e9dicament chez des personnes souffrant d'ob\u00e9sit\u00e9 hypothalamique, souvent \u00e0 la suite d'un traitement pour des tumeurs c\u00e9r\u00e9brales. Cette \u00e9tude refl\u00e8te la reconnaissance croissante du fait que l'ob\u00e9sit\u00e9 hypothalamique n\u00e9cessite une approche clinique diff\u00e9rente.
Plus d'informations :<\/strong> Lien vers le proc\u00e8s<\/a><\/p>\n\n\n\n

RM-718 pour l'ob\u00e9sit\u00e9 hypothalamique
<\/strong>Le RM-718 est un agoniste du r\u00e9cepteur de la m\u00e9lanocortine 4 (MC4R) de nouvelle g\u00e9n\u00e9ration con\u00e7u pour r\u00e9duire la faim et favoriser la r\u00e9gulation du poids sans augmenter la pression art\u00e9rielle ou la fr\u00e9quence cardiaque. Cette \u00e9tude de phase 1 vise \u00e0 d\u00e9terminer le dosage s\u00fbr et les effets initiaux chez les personnes atteintes d'HO. Cet essai repr\u00e9sente une avanc\u00e9e importante pour une communaut\u00e9 qui a toujours manqu\u00e9 d'options pharmacologiques fond\u00e9es sur des preuves.
Plus d'informations :<\/strong> Lien vers le proc\u00e8s<\/a><\/p>\n\n\n\n

Tirzepatide pour la perte de poids dans le syndrome de Prader-Willi, l'ob\u00e9sit\u00e9 hypothalamique et l'ob\u00e9sit\u00e9 g\u00e9n\u00e9rale\u00a0<\/strong><\/strong>
Cet essai \u00e9tudie le tirzepatide, un double agoniste des r\u00e9cepteurs GIP\/GLP-1, d\u00e9j\u00e0 approuv\u00e9 pour le diab\u00e8te de type 2 et l'ob\u00e9sit\u00e9, dans le SPW et l'HO. Son m\u00e9canisme peut \u00e9galement s'av\u00e9rer prometteur pour les personnes atteintes d'HO. Les sympt\u00f4mes, notamment l'hyperphagie et la dysr\u00e9gulation m\u00e9tabolique, rendent cet essai tr\u00e8s pertinent pour la communaut\u00e9 \u00e9largie des survivants de tumeurs c\u00e9r\u00e9brales hypothalamo-hypophysaires.
Plus d'informations<\/strong>: Lien vers le proc\u00e8s<\/a><\/p>\n\n\n\n

Essais dont le recrutement est termin\u00e9 et dont les donn\u00e9es ont \u00e9t\u00e9 publi\u00e9es<\/strong><\/h2>\n\n\n\n

Setmelanotide (IMCIVREE\u00ae)<\/strong>
Le setmelanotide, un agoniste du MC4R, a d\u00e9j\u00e0 montr\u00e9 des avantages cliniques dans des syndromes d'ob\u00e9sit\u00e9 g\u00e9n\u00e9tique rares. Il a \u00e9t\u00e9 test\u00e9 sur 120 patients, ce qui constitue l'essai contr\u00f4l\u00e9 randomis\u00e9 le plus important \u00e0 ce jour dans le domaine de l'ob\u00e9sit\u00e9. Des donn\u00e9es ont \u00e9t\u00e9 publi\u00e9es r\u00e9cemment lors de l'ENDO 2025, montrant des r\u00e9ductions significatives de l'IMC dans tous les groupes d'\u00e2ge. Ces r\u00e9sultats sont encourageants pour les patients et les cliniciens.
Communiqu\u00e9 de presse : Lire l'annonce<\/a><\/p>\n\n\n\n

Bivamelagon (LB54640)
<\/strong>Le bivamelagon est un agoniste oral du MC4R dont les essais de phase 2 ont r\u00e9cemment pris fin. Ce m\u00e9dicament offre la possibilit\u00e9 de prendre un comprim\u00e9 une fois par jour, ce qui pourrait r\u00e9duire le fardeau du traitement et en am\u00e9liorer l'accessibilit\u00e9. Dans la partie de l'essai de 14 semaines, en double aveugle, \u00e0 quatre bras et contr\u00f4l\u00e9e par placebo, le bivamelagon a permis des r\u00e9ductions statistiquement significatives et cliniquement significatives de l'indice de masse corporelle (IMC), en accord avec les r\u00e9ductions de l'IMC obtenues avec le traitement par le setmelanotide. 
Communiqu\u00e9 de presse : Lire l'annonce<\/a><\/p>\n\n\n\n

Pourquoi c'est important<\/strong><\/h3>\n\n\n\n

La recherche clinique est une \u00e9tape essentielle pour transformer le paysage des soins de l'ob\u00e9sit\u00e9 hypothalamique. Ces essais ne repr\u00e9sentent pas seulement un progr\u00e8s scientifique, ils sont porteurs d'espoir. Pour les familles confront\u00e9es \u00e0 une maladie mal comprise et n\u00e9glig\u00e9e, la disponibilit\u00e9 de nouvelles th\u00e9rapies fond\u00e9es sur la biologie du cerveau pourrait changer la vie.<\/p>\n\n\n\n

\u00c0 la Fondation Raymond A. Wood, nous restons d\u00e9termin\u00e9s \u00e0 plaider en faveur d'une recherche qui refl\u00e8te les exp\u00e9riences v\u00e9cues par notre communaut\u00e9. Nous continuerons \u00e0 partager des mises \u00e0 jour sur ces \u00e9tudes et d'autres au fur et \u00e0 mesure que les donn\u00e9es seront disponibles.<\/p>\n\n\n\n

Pour plus d'informations ou de conseils sur les essais cliniques, consultez notre site web Recherche d'essais cliniques<\/a> <\/a>ou rejoignez-nous en novembre pour notre Conf\u00e9rence des familles sur les tumeurs c\u00e9r\u00e9brales hypophysaires<\/a> \u00e0 Philadelphie.<\/p>","protected":false},"excerpt":{"rendered":"

Les essais cliniques en cours et les donn\u00e9es r\u00e9cemment publi\u00e9es offrent un espoir pour l'HO Pour les survivants de la maladie hypothalamo-hypophysaire ... Lire plus<\/a><\/p>","protected":false},"author":6,"featured_media":14638,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[29,20],"tags":[],"class_list":["post-14637","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-hypothalamic-obesity","category-latest-research","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-33","no-featured-image-padding"],"acf":[],"yoast_head":"\nNew Frontiers in Hypothalamic Obesity Research - Raymond A. Wood Foundation<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rawoodfoundation.org\/fr\/2025\/07\/16\/nouvelles-frontieres-dans-la-recherche-sur-lobesite-hypothalamique\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Frontiers in Hypothalamic Obesity Research - Raymond A. Wood Foundation\" \/>\n<meta property=\"og:description\" content=\"Current Clinical Trials and Newly Released Data Offering Hope for HO For survivors of hypothalamic-pituitary ... Lire plus\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rawoodfoundation.org\/fr\/2025\/07\/16\/nouvelles-frontieres-dans-la-recherche-sur-lobesite-hypothalamique\/\" \/>\n<meta property=\"og:site_name\" content=\"Raymond A. Wood Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/rawoodfoundation\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-16T14:48:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-29T13:00:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rawoodfoundation.org\/wp-content\/uploads\/2025\/07\/Copy-of-Copy-of-Blog-Post-Image.png\" \/>\n\t<meta property=\"og:image:width\" content=\"477\" \/>\n\t<meta property=\"og:image:height\" content=\"326\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"RAWF\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@rawoodfound\" \/>\n<meta name=\"twitter:site\" content=\"@rawoodfound\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"RAWF\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/\"},\"author\":{\"name\":\"RAWF\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#\\\/schema\\\/person\\\/12e3ee04f1646efc9cbbc13eb127f3b4\"},\"headline\":\"New Frontiers in Hypothalamic Obesity Research\",\"datePublished\":\"2025-07-16T14:48:43+00:00\",\"dateModified\":\"2025-10-29T13:00:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/\"},\"wordCount\":604,\"publisher\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/Copy-of-Copy-of-Blog-Post-Image.png\",\"articleSection\":[\"Hypothalamic Obesity\",\"Latest Research\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/\",\"url\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/\",\"name\":\"New Frontiers in Hypothalamic Obesity Research - Raymond A. Wood Foundation\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/Copy-of-Copy-of-Blog-Post-Image.png\",\"datePublished\":\"2025-07-16T14:48:43+00:00\",\"dateModified\":\"2025-10-29T13:00:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/Copy-of-Copy-of-Blog-Post-Image.png\",\"contentUrl\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/Copy-of-Copy-of-Blog-Post-Image.png\",\"width\":477,\"height\":326,\"caption\":\"Image of medications with title New Frontiers in Hypothalamic Obesity: Clinical Trials Offering Hope\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/2025\\\/07\\\/16\\\/new-frontiers-in-hypothalamic-obesity-research\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Frontiers in Hypothalamic Obesity Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#website\",\"url\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/\",\"name\":\"Raymond A. Wood Foundation\",\"description\":\"The mission of the RAWF is to provide quality of life support for childhood brain tumor survivors and their families.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#organization\",\"name\":\"Raymond A. Wood Foundation\",\"url\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Raymond-A-Wood-Foundation-logo.webp\",\"contentUrl\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Raymond-A-Wood-Foundation-logo.webp\",\"width\":470,\"height\":128,\"caption\":\"Raymond A. Wood Foundation\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/rawoodfoundation\",\"https:\\\/\\\/x.com\\\/rawoodfound\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/#\\\/schema\\\/person\\\/12e3ee04f1646efc9cbbc13eb127f3b4\",\"name\":\"RAWF\",\"url\":\"https:\\\/\\\/www.rawoodfoundation.org\\\/fr\\\/author\\\/rawf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nouvelles fronti\u00e8res de la recherche sur l'ob\u00e9sit\u00e9 hypothalamique - Raymond A. Wood Foundation","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rawoodfoundation.org\/fr\/2025\/07\/16\/nouvelles-frontieres-dans-la-recherche-sur-lobesite-hypothalamique\/","og_locale":"fr_FR","og_type":"article","og_title":"New Frontiers in Hypothalamic Obesity Research - Raymond A. Wood Foundation","og_description":"Current Clinical Trials and Newly Released Data Offering Hope for HO For survivors of hypothalamic-pituitary ... Lire plus","og_url":"https:\/\/www.rawoodfoundation.org\/fr\/2025\/07\/16\/nouvelles-frontieres-dans-la-recherche-sur-lobesite-hypothalamique\/","og_site_name":"Raymond A. Wood Foundation","article_publisher":"https:\/\/www.facebook.com\/rawoodfoundation","article_published_time":"2025-07-16T14:48:43+00:00","article_modified_time":"2025-10-29T13:00:38+00:00","og_image":[{"width":477,"height":326,"url":"https:\/\/www.rawoodfoundation.org\/wp-content\/uploads\/2025\/07\/Copy-of-Copy-of-Blog-Post-Image.png","type":"image\/png"}],"author":"RAWF","twitter_card":"summary_large_image","twitter_creator":"@rawoodfound","twitter_site":"@rawoodfound","twitter_misc":{"Written by":"RAWF","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/#article","isPartOf":{"@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/"},"author":{"name":"RAWF","@id":"https:\/\/www.rawoodfoundation.org\/#\/schema\/person\/12e3ee04f1646efc9cbbc13eb127f3b4"},"headline":"New Frontiers in Hypothalamic Obesity Research","datePublished":"2025-07-16T14:48:43+00:00","dateModified":"2025-10-29T13:00:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/"},"wordCount":604,"publisher":{"@id":"https:\/\/www.rawoodfoundation.org\/#organization"},"image":{"@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rawoodfoundation.org\/wp-content\/uploads\/2025\/07\/Copy-of-Copy-of-Blog-Post-Image.png","articleSection":["Hypothalamic Obesity","Latest Research"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/","url":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/","name":"Nouvelles fronti\u00e8res de la recherche sur l'ob\u00e9sit\u00e9 hypothalamique - Raymond A. Wood Foundation","isPartOf":{"@id":"https:\/\/www.rawoodfoundation.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/#primaryimage"},"image":{"@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rawoodfoundation.org\/wp-content\/uploads\/2025\/07\/Copy-of-Copy-of-Blog-Post-Image.png","datePublished":"2025-07-16T14:48:43+00:00","dateModified":"2025-10-29T13:00:38+00:00","breadcrumb":{"@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/#primaryimage","url":"https:\/\/www.rawoodfoundation.org\/wp-content\/uploads\/2025\/07\/Copy-of-Copy-of-Blog-Post-Image.png","contentUrl":"https:\/\/www.rawoodfoundation.org\/wp-content\/uploads\/2025\/07\/Copy-of-Copy-of-Blog-Post-Image.png","width":477,"height":326,"caption":"Image of medications with title New Frontiers in Hypothalamic Obesity: Clinical Trials Offering Hope"},{"@type":"BreadcrumbList","@id":"https:\/\/www.rawoodfoundation.org\/2025\/07\/16\/new-frontiers-in-hypothalamic-obesity-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rawoodfoundation.org\/"},{"@type":"ListItem","position":2,"name":"New Frontiers in Hypothalamic Obesity Research"}]},{"@type":"WebSite","@id":"https:\/\/www.rawoodfoundation.org\/#website","url":"https:\/\/www.rawoodfoundation.org\/","name":"Fondation Raymond A. Wood","description":"La mission de la RAWF est d'apporter un soutien \u00e0 la qualit\u00e9 de vie des survivants de tumeurs c\u00e9r\u00e9brales infantiles et de leurs familles.","publisher":{"@id":"https:\/\/www.rawoodfoundation.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rawoodfoundation.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.rawoodfoundation.org\/#organization","name":"Fondation Raymond A. Wood","url":"https:\/\/www.rawoodfoundation.org\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.rawoodfoundation.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.rawoodfoundation.org\/wp-content\/uploads\/2023\/07\/Raymond-A-Wood-Foundation-logo.webp","contentUrl":"https:\/\/www.rawoodfoundation.org\/wp-content\/uploads\/2023\/07\/Raymond-A-Wood-Foundation-logo.webp","width":470,"height":128,"caption":"Raymond A. Wood Foundation"},"image":{"@id":"https:\/\/www.rawoodfoundation.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/rawoodfoundation","https:\/\/x.com\/rawoodfound"]},{"@type":"Person","@id":"https:\/\/www.rawoodfoundation.org\/#\/schema\/person\/12e3ee04f1646efc9cbbc13eb127f3b4","name":"RAWF","url":"https:\/\/www.rawoodfoundation.org\/fr\/author\/rawf\/"}]}},"_links":{"self":[{"href":"https:\/\/www.rawoodfoundation.org\/fr\/wp-json\/wp\/v2\/posts\/14637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rawoodfoundation.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rawoodfoundation.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rawoodfoundation.org\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rawoodfoundation.org\/fr\/wp-json\/wp\/v2\/comments?post=14637"}],"version-history":[{"count":5,"href":"https:\/\/www.rawoodfoundation.org\/fr\/wp-json\/wp\/v2\/posts\/14637\/revisions"}],"predecessor-version":[{"id":17619,"href":"https:\/\/www.rawoodfoundation.org\/fr\/wp-json\/wp\/v2\/posts\/14637\/revisions\/17619"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rawoodfoundation.org\/fr\/wp-json\/wp\/v2\/media\/14638"}],"wp:attachment":[{"href":"https:\/\/www.rawoodfoundation.org\/fr\/wp-json\/wp\/v2\/media?parent=14637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rawoodfoundation.org\/fr\/wp-json\/wp\/v2\/categories?post=14637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rawoodfoundation.org\/fr\/wp-json\/wp\/v2\/tags?post=14637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}